Healthcare: Cancer is a heterogeneous and multifactorial disease. Among multiple factors, it may be caused by errors, or ...

On Thursday, genetics-led consumer healthcare company 23andMe Holding Co. (NASDAQ:ME) announced a business restructuring to ...

The familial trend, it turned out, was linked to a genetic mutation. That meant Bill might also be at risk for the disease.

The global market for cancer-focused genetic testing services is on a transformative growth trajectory, with projections estimating a market size of USD 8,472.70 million by 2024, and an expected ...

The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers focusing on maintaining ...

DNA-testing service 23andMe is making substantial efforts to nurse its feeble genetic core back to health. The company will ...

23andMe is laying off 40 percent of its employees, or over 200 workers, as the company attempts to recover from last year’s ...

Genetic testing is a vital tool in combating hereditary gynecologic cancers, enabling early detection and personalised care.

Increased awareness of genetic testing’s role in disease prevention is driving market growth. Saudi Arabia's genetic testing ...

Relevant genes to test for hereditary prostate cancer include ATM, BRCA1, BRCA2, CHEK2, HOXB13, and TP53, according to the guidelines. For all four cancer types included in these guidelines, NCCN also ...

QUT scientists have uncovered functionality of a genetic variant in the prostate specific antigen (PSA) gene to improve the current diagnostic test to help distinguish aggressive from non-aggressive ...

Scientists uncover functionality of a genetic variant in the prostate specific antigen (PSA) gene to improve the current diagnostic test to help distinguish aggressive from non-aggressive prostate ...